Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBIT Margin (2018 - 2025)

Sunshine Biopharma's EBIT Margin history spans 9 years, with the latest figure at 20.87% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 37.0% year-over-year to 20.87%; the TTM value through Dec 2025 reached 17.15%, down 63.0%, while the annual FY2025 figure was 17.15%, 49.0% down from the prior year.
  • EBIT Margin reached 20.87% in Q4 2025 per SBFM's latest filing, down from 11.54% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 11.54% in Q3 2025 to a low of 3184.5% in Q1 2021.
  • Average EBIT Margin over 5 years is 439.95%, with a median of 21.54% recorded in 2025.
  • Peak YoY movement for EBIT Margin: plummeted -284493bps in 2021, then surged 218701bps in 2022.
  • A 5-year view of EBIT Margin shows it stood at 328.52% in 2021, then tumbled by -81bps to 593.01% in 2022, then soared by 97bps to 15.46% in 2023, then crashed by -37bps to 21.24% in 2024, then rose by 2bps to 20.87% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBIT Margin are 20.87% (Q4 2025), 11.54% (Q3 2025), and 21.83% (Q2 2025).